CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To examine the role of IFN-γ in CML cells in the context of TKI treatment, Madapura et al. treated CML cell lines and primary human CML CD34+ cells with IFN-γ with and without imatinib.